Page 3 - Isk Bioscience News Today

Novavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine approved for use in adolescents aged 12 through 17 years in South Korea GAITHERSBURG, Md., Aug. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner, SK bioscience, has received a Post Approval Change Application approval from the Korean Ministry of Food ...

SK Bioscience seeks approval for COVID vaccine in Europe

SEOUL, South Korea (AP) — Health officials in South Korea on Wednesday approved the...

Korea approves use of 1st local COVID-19 vaccine from SK Bioscience

SK Bioscience gets final approval for Koreas 1st COVID-19 vaccine

SEOUL: Taking a major step toward achieving vaccine sovereignty to fight against the pandemic,  South Korea on Wednesday approved the u... | News Track

Samsung, SK in race to gain lead in CDMO market

SKYCovione is a self-assembled nanoparticle vaccine candidate targeting the receptor binding domain of the SARS-CoV-2 Spike protein for the parental SARS-Cov-2.

SK bioscience closer to obtaining approval for COVID-19 vaccine

Merck's former China head will return to the Big Pharma to lead international human health operations after a short stint at a Chinese company.